卖什么
MOGLU, a needle-free wearable continuous glucose monitor using Raman spectroscopy; the site reports 11.34% MARD with 100% of readings in Parkes zones A/B in an IRB-approved study with MIT.
商业模式拆解
触发点：什么让他们现在购买？
Diabetes patients wanting to avoid needle sensors; June 1 2026 peer-reviewed MIT study (JDST) claims accuracy comparable to FDA-cleared Abbott and Dexcom devices.
工作流：什么输入变成什么输出？
Wearable (target 40x30x16 mm) uses band-pass Raman spectroscopy to read glucose non-invasively instead of a needle-based sensor.
经济账：省了什么，怎么收费？
未核实Pre-revenue device developer; value rests on a consumer wearable CGM replacing needle-based sensors (not stated on site).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-09-23 | A 轮 | 50억원 | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.